Here’s what you should know.
1. The Rezum system is a minimally invasive therapy for patients with symptomatic benign prostatic hyperplasia.
2. Boston Scientific is incorporating NxThera into its urology and pelvic health business.
3. Boston Scientific acquired NxThera because the company feels the Rezum system compliments its existing offerings for symptomatic BPH.
Boston Scientific Executive Vice President and MedSurg President Dave Pierce said, “We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side effects of medications.”
More articles on supply chain:
Stryker CEO sees orthopedics moving to ASCs — But how fast?
4 things to know about Salix Pharmaceuticals
Exact Sciences surpasses investor predictions — Cologuard revenue hits $90.3M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
